Skip to content

Pipeline Report

Executive Summary

The HCLS AI Factory represents a breakthrough in precision medicine, delivering an end-to-end platform that transforms raw patient DNA sequencing data into novel drug candidates in under 5 hours. Built on NVIDIA's accelerated computing stack and powered by advanced AI, this platform reduces what traditionally takes months of manual analysis to a streamlined, GPU-accelerated workflow.

Key Achievements

Metric Value Impact
Processing Time ~5 hours 99% reduction from traditional methods
Lines of Code 36,000+ Production-grade implementation
Variant Coverage 3.56M Comprehensive genomic database
Target Genes 201 Clinically validated targets
Druggability Rate 85% High therapeutic potential

Platform Architecture

                    PRECISION MEDICINE TO DRUG DISCOVERY
    ════════════════════════════════════════════════════════════════

    ┌─────────────────┐     ┌─────────────────┐     ┌─────────────────┐
    │                 │     │                 │     │                 │
    │    STAGE 1      │────▶│    STAGE 2      │────▶│    STAGE 3      │
    │                 │     │                 │     │                 │
    │   GENOMICS      │     │   RAG/CHAT      │     │   DRUG          │
    │   PIPELINE      │     │   PIPELINE      │     │   DISCOVERY     │
    │                 │     │                 │     │                 │
    │  ┌───────────┐  │     │  ┌───────────┐  │     │  ┌───────────┐  │
    │  │  FASTQ    │  │     │  │  VCF      │  │     │  │  TARGET   │  │
    │  │    ↓      │  │     │  │    ↓      │  │     │  │    ↓      │  │
    │  │  VCF     │  │     │  │  TARGET   │  │     │  │ MOLECULES │  │
    │  └───────────┘  │     │  └───────────┘  │     │  └───────────┘  │
    │                 │     │                 │     │                 │
    │  120-240 min      │     │  Interactive    │     │  Minutes        │
    └─────────────────┘     └─────────────────┘     └─────────────────┘
            │                       │                       │
            └───────────────────────┴───────────────────────┘
                                    │
                    ┌───────────────────────────────┐
                    │     NVIDIA DGX SPARK          │
                    │  128GB unified LPDDR5x | 144  │
                    └───────────────────────────────┘

Stage 1: Genomics Pipeline

Overview

The Genomics Pipeline transforms raw DNA sequencing data (FASTQ) into variant calls (VCF) using NVIDIA Parabricks, achieving 10-50x acceleration over traditional CPU-based methods.

Technical Specifications

Component Technology Performance
Alignment BWA-MEM2 (GPU-accelerated) 20-45 minutes
Sorting Coordinate sorting with deduplication Included
Indexing samtools index + flagstat 2-5 minutes
Variant Calling Google DeepVariant (GPU) 10-35 minutes

Data Flow

┌──────────────────────────────────────────────────────────────────────┐
│                        GENOMICS PIPELINE                              │
├──────────────────────────────────────────────────────────────────────┤
│                                                                       │
│   INPUT                    PROCESSING                    OUTPUT       │
│   ─────                    ──────────                    ──────       │
│                                                                       │
│   ┌─────────┐    ┌─────────────────────────────┐    ┌─────────┐     │
│   │ FASTQ   │    │                             │    │  BAM    │     │
│   │ R1/R2   │───▶│     NVIDIA PARABRICKS       │───▶│  File   │     │
│   │ ~200GB  │    │     fq2bam + DeepVariant    │    │ ~100GB  │     │
│   └─────────┘    │                             │    └────┬────┘     │
│                  │   ┌───────────────────────┐ │         │          │
│   ┌─────────┐    │   │ GRCh38 Reference      │ │    ┌────▼────┐     │
│   │Reference│───▶│   │ Genome (3.1GB)        │ │    │  VCF    │     │
│   │ GRCh38  │    │   └───────────────────────┘ │    │  File   │     │
│   └─────────┘    │                             │    │ ~11.7M  │     │
│                  └─────────────────────────────┘    │variants │     │
│                                                      └─────────┘     │
│                                                                       │
│   TIMING: 120-240 minutes (vs. 24-48 hours on CPU)                     │
│                                                                       │
└──────────────────────────────────────────────────────────────────────┘

Performance Metrics

Metric Value
Input Size ~200 GB (paired-end FASTQ)
Output Variants ~11.7 million
Processing Time 120-240 minutes
GPU Utilization 85-95%
Accuracy >99% (DeepVariant)

Stage 2: RAG/Chat Pipeline

Overview

The RAG (Retrieval-Augmented Generation) Pipeline enables natural language queries across millions of genomic variants, synthesizing AI-powered answers grounded in clinical evidence.

Technical Specifications

Component Technology Capacity
Vector Database Milvus 3.56M embeddings
Embedding Model BGE-small-en-v1.5 384 dimensions
Knowledge Base Clinker 201 genes, 150+ diseases
LLM Claude (Anthropic) claude-sonnet-4
Clinical Data ClinVar 4.1M variants
AI Predictions AlphaMissense 71M predictions

Architecture

┌──────────────────────────────────────────────────────────────────────┐
│                         RAG/CHAT PIPELINE                             │
├──────────────────────────────────────────────────────────────────────┤
│                                                                       │
│                        ┌─────────────────┐                           │
│                        │   User Query    │                           │
│                        │ "What variants  │                           │
│                        │  affect VCP?"   │                           │
│                        └────────┬────────┘                           │
│                                 │                                     │
│                                 ▼                                     │
│   ┌─────────────────────────────────────────────────────────────┐   │
│   │                    EMBEDDING LAYER                           │   │
│   │                  BGE-small-en-v1.5                           │   │
│   │                   384 Dimensions                             │   │
│   └─────────────────────────────┬───────────────────────────────┘   │
│                                 │                                     │
│                                 ▼                                     │
│   ┌─────────────────────────────────────────────────────────────┐   │
│   │                     MILVUS VECTOR DB                         │   │
│   │  ┌──────────────┐  ┌──────────────┐  ┌──────────────┐       │   │
│   │  │   ClinVar    │  │ AlphaMissense│  │   Clinker    │       │   │
│   │  │  4.1M vars   │  │  71M scores  │  │  201 genes   │       │   │
│   │  └──────────────┘  └──────────────┘  └──────────────┘       │   │
│   └─────────────────────────────┬───────────────────────────────┘   │
│                                 │                                     │
│                                 ▼                                     │
│   ┌─────────────────────────────────────────────────────────────┐   │
│   │                      CLAUDE LLM                              │   │
│   │              Evidence Synthesis & Reasoning                  │   │
│   │                 Grounded in Citations                        │   │
│   └─────────────────────────────┬───────────────────────────────┘   │
│                                 │                                     │
│                                 ▼                                     │
│                        ┌─────────────────┐                           │
│                        │  AI Response    │                           │
│                        │  + Citations    │                           │
│                        │  + Evidence     │                           │
│                        └─────────────────┘                           │
│                                                                       │
└──────────────────────────────────────────────────────────────────────┘

Knowledge Base Coverage

Therapeutic Area Target Genes Key Diseases
Oncology 45 Breast, Lung, Colorectal Cancers
Neurology 38 ALS, FTD, Parkinson's, Alzheimer's
Rare Disease 52 Inherited Metabolic Disorders
Cardiovascular 28 Cardiomyopathy, Arrhythmia
Immunology 22 Autoimmune Disorders
Ophthalmology 16 Retinal Dystrophies

Sample Queries

Query: "What pathogenic variants are associated with VCP?"

Response: Based on clinical evidence from ClinVar and AlphaMissense:

• VCP R155H (rs121909331) - Pathogenic
  - Associated with IBMPFD (Inclusion Body Myopathy with Paget's Disease)
  - AlphaMissense Score: 0.94 (Likely Pathogenic)

• VCP R191Q (rs121909332) - Pathogenic
  - Causes familial ALS and FTD
  - 85% druggability confidence

• VCP A232E (rs121909333) - Pathogenic
  - Multi-system proteinopathy
  - Structure available: PDB 8OOI

Target Hypothesis: VCP is a validated therapeutic target for
neurodegenerative disease with known inhibitors in clinical development.

Stage 3: Drug Discovery Pipeline

Overview

The Drug Discovery Pipeline leverages NVIDIA BioNeMo NIM microservices to generate novel drug-like molecules from validated protein targets, complete with binding pose predictions and drug-likeness scoring.

Technical Specifications

Component Technology Function
Structure Retrieval RCSB PDB API Cryo-EM/X-ray structures
Molecule Generation BioNeMo MolMIM Novel analog creation
Molecular Docking BioNeMo DiffDock Binding pose prediction
3D Conformers RDKit Energy minimization
Drug Scoring QED + Lipinski Drug-likeness evaluation
Report Generation ReportLab Professional PDF output

Pipeline Flow

┌──────────────────────────────────────────────────────────────────────┐
│                      DRUG DISCOVERY PIPELINE                          │
├──────────────────────────────────────────────────────────────────────┤
│                                                                       │
│  PHASE 1: STRUCTURE RETRIEVAL                                        │
│  ─────────────────────────────                                       │
│  ┌─────────────┐    ┌─────────────────────────────────────────┐     │
│  │   Target    │───▶│            RCSB PDB API                  │     │
│  │   (VCP)     │    │   8OOI: WT Hexamer (2.9Å, Cryo-EM)      │     │
│  └─────────────┘    │   9DIL: Mutant (3.2Å)                    │     │
│                     │   5FTK: +CB-5083 Inhibitor (2.3Å)        │     │
│                     └─────────────────────────────────────────┘     │
│                                       │                              │
│                                       ▼                              │
│  PHASE 2: MOLECULE GENERATION                                        │
│  ────────────────────────────                                        │
│  ┌─────────────┐    ┌─────────────────────────────────────────┐     │
│  │ Seed Mol    │───▶│           BioNeMo MolMIM                 │     │
│  │  (CB-5083)  │    │      Masked Language Modeling            │     │
│  │   SMILES    │    │      Generate Novel Analogs              │     │
│  └─────────────┘    └─────────────────────────────────────────┘     │
│                                       │                              │
│                                       ▼                              │
│  PHASE 3: MOLECULAR DOCKING                                          │
│  ──────────────────────────                                          │
│  ┌─────────────────────────────────────────────────────────────┐    │
│  │                    BioNeMo DiffDock                          │    │
│  │           Diffusion-Based Docking Predictions                │    │
│  │              Binding Pose Generation                         │    │
│  └─────────────────────────────────────────────────────────────┘    │
│                                       │                              │
│                                       ▼                              │
│  PHASE 4: SCORING & RANKING                                          │
│  ──────────────────────────                                          │
│  ┌────────────────┐ ┌────────────────┐ ┌────────────────┐           │
│  │   Lipinski     │ │      QED       │ │     ADMET      │           │
│  │   Rule of 5    │ │    Score       │ │   Properties   │           │
│  │   MW ≤ 500     │ │   0.0-1.0      │ │   Absorption   │           │
│  │   LogP ≤ 5     │ │  Drug-likeness │ │   Metabolism   │           │
│  └────────────────┘ └────────────────┘ └────────────────┘           │
│                                       │                              │
│                                       ▼                              │
│  PHASE 5: REPORT GENERATION                                          │
│  ──────────────────────────                                          │
│  ┌─────────────────────────────────────────────────────────────┐    │
│  │              VCP_Drug_Candidate_Report.pdf                   │    │
│  │   • Executive Summary        • Ranked Candidates             │    │
│  │   • Structure Analysis       • Scoring Details               │    │
│  │   • Binding Site Maps        • Next Steps                    │    │
│  └─────────────────────────────────────────────────────────────┘    │
│                                                                       │
└──────────────────────────────────────────────────────────────────────┘

Drug-Likeness Criteria

Rule Criteria Purpose
Lipinski Rule 1 MW ≤ 500 Da Oral bioavailability
Lipinski Rule 2 LogP ≤ 5 Membrane permeability
Lipinski Rule 3 H-Bond Donors ≤ 5 Absorption
Lipinski Rule 4 H-Bond Acceptors ≤ 10 Solubility
QED Score 0.0 - 1.0 Overall drug-likeness

Infrastructure & Monitoring

NVIDIA DGX Spark Specifications

Component Specification
GPU NVIDIA GB10 (Blackwell)
Unified Memory 128 GB LPDDR5x (shared CPU/GPU)
CPU ARM64 Cores
Storage 2+ TB NVMe
Network 100 GbE

Service Architecture

Port Service Status
8080 Landing Page Active
5000 Genomics Portal Active
5001 RAG/Chat API Active
8501 RAG Chat Interface Active
8505 Drug Discovery UI Active
8510 Discovery Portal Active
19530 Milvus Vector DB Active
3000 Grafana Active
9099 Prometheus Active
9100 Node Exporter Active
9400 DCGM Exporter Active

Monitoring Dashboard

┌──────────────────────────────────────────────────────────────────────┐
│                    NVIDIA DGX SPARK GPU MONITORING                    │
├──────────────────────────────────────────────────────────────────────┤
│                                                                       │
│  ┌────────────────┐  ┌────────────────┐  ┌────────────────┐         │
│  │ GPU Utilization│  │ GPU Temperature│  │  GPU Power     │         │
│  │      85%       │  │     62°C       │  │    320W        │         │
│  │   ████████░░   │  │   ██████░░░░   │  │   ████████░░   │         │
│  └────────────────┘  └────────────────┘  └────────────────┘         │
│                                                                       │
│  ┌────────────────┐  ┌────────────────┐  ┌────────────────┐         │
│  │ CPU Utilization│  │Memory Bandwidth│  │ NVMe Throughput│         │
│  │      45%       │  │   450 GB/s     │  │   2.8 GB/s     │         │
│  │   ████░░░░░░   │  │   ███████░░░   │  │   ███████░░░   │         │
│  └────────────────┘  └────────────────┘  └────────────────┘         │
│                                                                       │
└──────────────────────────────────────────────────────────────────────┘

Platform Statistics Summary

Codebase Metrics

Pipeline Python JavaScript Shell Markdown CSS/HTML Total
Genomics 1,839 1,344 2,636 2,510 1,671 10,000
RAG/Chat 9,409 716 349 1,797 975 13,321
Drug Discovery 5,332 - 55 1,102 234 6,723
Landing Page 400 750 100 450 708 2,408
Documentation - - - 3,540 - 3,540
Total 16,980 2,810 3,140 9,399 3,588 ~36,000

Data Assets

Asset Count Source
Variant Embeddings 3,561,170 VCF + Annotations
ClinVar Variants 4,100,000 NCBI ClinVar
AlphaMissense Predictions 71,000,000 DeepMind
Target Genes 201 Clinker Knowledge Base
Disease Associations 150+ Curated Database
Therapeutic Areas 13 Clinical Classification
Druggable Targets 171 Druggability Analysis

Technology Stack

Core Technologies

Layer Technology Purpose
Compute NVIDIA DGX Spark GPU-accelerated processing
Genomics NVIDIA Parabricks 4.6 Variant calling pipeline
AI/ML NVIDIA BioNeMo NIM Drug discovery models
LLM Claude (Anthropic) Natural language reasoning
Vector DB Milvus Similarity search
Embeddings BGE-small-en-v1.5 Semantic encoding
Web Flask + Streamlit User interfaces
Monitoring Grafana + Prometheus System observability
Container Docker + NVIDIA Runtime Service orchestration

AI Models

Model Provider Application
DeepVariant Google Variant calling (>99% accuracy)
BGE-small-en-v1.5 BAAI Semantic embeddings
Claude Sonnet 4 Anthropic Evidence synthesis
MolMIM NVIDIA BioNeMo Molecule generation
DiffDock NVIDIA BioNeMo Molecular docking
AlphaMissense DeepMind Pathogenicity prediction

Business Value

Time Savings

Process Traditional AI Factory Improvement
FASTQ to VCF 24-48 hours 120-240 min 50x faster
Variant Interpretation 2-4 weeks Minutes 1000x faster
Target Identification 1-3 months Hours 100x faster
Lead Generation 6-12 months Hours 1000x faster
Total Pipeline 12-18 months ~5 hours 99% reduction

Cost Efficiency

Factor Impact
Compute Time Reduction 50-100x lower GPU hours
Manual Analysis Reduction 90% fewer specialist hours
Iteration Speed 10x faster hypothesis testing
Error Reduction AI-validated annotations

Conclusion

The HCLS AI Factory delivers a production-ready platform for precision medicine to drug discovery, demonstrating the transformative potential of GPU-accelerated computing and AI in healthcare.

Key Differentiators

  • End-to-End Integration: Single platform from DNA to drug candidates
  • GPU Acceleration: NVIDIA Parabricks and BioNeMo for 10-100x speedups
  • AI-Powered Insights: Claude LLM for evidence synthesis
  • Clinical Grounding: 4.1M ClinVar variants with 71M AI predictions
  • Production Ready: 36,000+ lines of tested code